Publications by authors named "T D W Luke"
Article Synopsis
- - The study investigates how the SSRI escitalopram affects reactive aggression in women with high premenstrual irritability and anger, showing that it reduces irritability during treatment but not significantly in all aggression tasks.
- - Participants (N=34) underwent a single-blind, cross-over design where they were given either escitalopram or a placebo during different menstrual cycles and completed aggression tasks to measure their responses.
- - Results revealed that while escitalopram reduced irritability, it only decreased reactive aggression in a specific group of participants, emphasizing the need to understand individual differences in how premenstrual emotions manifest.
Article Synopsis
- * SAB-163 is a new therapeutic treatment developed from transchromosomic bovine plasma, showing strong effectiveness against multiple hantavirus strains and extended bioavailability in animal models.
- * The treatment has demonstrated protective effects in hamsters when administered around the time of exposure and is now ready for phase 1 clinical trials after passing safety and efficacy tests.
We introduce the disclosure-outcomes management model. The model views disclosure in intelligence interviews as a behaviour interviewees use to profitably navigate self-interest dilemmas. We theorized that interviewees compare the potential outcomes of disclosing to their self-interests.
View Article and Find Full Text PDFBackground: We evaluated the fully human polyclonal antibody product SAB-185 in a phase 3 trial for COVID-19.
Methods: Nonhospitalized high-risk adults within 7 days of symptom onset were randomized 1:1 to open-label SAB-185 3840 units/kg or casirivimab/imdevimab 1200 mg. Noninferiority comparison was undertaken for pre-Omicron population (casirivimab/imdevimab expected to be fully active) and superiority comparison for the Omicron population (casirivimab/imdevimab not expected to be active).
Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-dependent enhancement (ADE) of disease as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral/ocular) or inhalation using a small particle aerosol.
View Article and Find Full Text PDF